Search

Research on Key Issues and Countermeasures Faced by Higher Education Institutions in the Development of Suzhou's Biomedical Innovation Consortium

Author(s)

Jing Chen1,*, Hongni Wei2

Affiliation(s)

1Suzhou Vocational Institute of Industrial Technology, Suzhou, China 2School of Business, Guangdong University of Foreign Studies, Guangzhou, China *Corresponding Author

Abstract

The biopharmaceutical industry stands as Suzhou's premier sector and remains one of the city's long-term strategic priorities, boasting immense growth potential and dynamic development. Establishing innovation consortia within this field—led by industry leaders, supported by academic institutions, and fostering collaborative synergy among all innovation elements—enables breakthroughs in critical core technologies. This approach not only represents Suzhou's strategic choice to leverage its comparative advantages but also constitutes a profound strategy for driving high-quality development. However, in practice, issues such as inadequate institutional mechanisms and a shortage of high-calibre leading enterprises within the sector have indeed hampered the formation of these consortia. Consequently, universities find themselves sidelined, unable to maximize their intellectual support role. Identifying the underlying causes and proposing targeted pathways and measures is therefore an urgent priority.

Keywords

Biopharmaceuticals; Innovation Consortiums; Higher Education Institutions; Critical Issues; Countermeasures

References

[1]Yue Yingchu, Huo Guoqing. Research on Interest Conflicts and Strategic Interactions Among Stakeholders in Innovation Consortia. Studies in Science of Science, 2024, 42(5): 1088-1097, 1120. [2]Evelien P M, croonen, Huizingh E K. Why not all 'winners' are successful: explaining project performance of publicly funded innovation consortia. Technological Forecasting & SocialChange, 2025, 216: 124124. [3]Zhuoran Shan, Yulian Tan, Man Yuan, et al. Spatial Pattern and Organisation of the Biomedical Industry Chain in the Wuhan Metropolitan Area. Economic Geography, 2025, 45(1): 122-133. [4]Wang Luwei, Zhang Yizhen, Ren Chuantang et al. Spatial Organisation Patterns of the Biopharmaceutical Industry in China's Three Major Urban Agglomerations: A Study Based on the ‘Three-Dimensional Three-Network’ Framework. Geographical Research, 2023, 42(10): 2696-2712. [5]Wan Yuanyuan, Wang Qiuyu, Zeng Gang et al. The Mechanism of Innovation Networking Between Higher Education Institutions and Biopharmaceutical Enterprises: A Case Study of the Yangtze River Delta Region. Economic Geography, 2022, 42(7): 146-158. [6]Wang Jiawei, Zeng Gang, Chen Pengxin et al. Research on the Evolutionary Mechanisms of Non-Local Innovation Networks in the Yangtze River Delta Biomedical Industry. Progress in Geography, 2025, 44(4): 754-767. [7]Henry Wai-chung Yeung. Regional worlds: From related variety in regional diversification to strategic coupling in global production networks. Regional Studies, 2021, 55(6): 989-1010. [8]Yu Jing. Reflections on the Planning of Shanghai's Biopharmaceutical Industry Layout from a Global Urban Perspective. Shanghai Urban Planning Review, 2021(2): 120-127. [9]Wang Yue, Yue Jun, Du Yan et al. Evaluation and Optimisation Recommendations for Shenzhen's Innovative Industrial Spatial Policies from a Supply-Demand Perspective. Planners, 2024, 40(6): 62-71. [10]Hu Haipeng, Yuan Yong. Policy and Theoretical Research on Promoting Innovation and Development in the Biopharmaceutical Industry. Decision-Making & Consultancy, 2022(4): 62-67.